Richard Hoffman is a partner in Goodwin’s Life Sciences group. Richard is a lawyer, consultant and entrepreneur in the life sciences industry, with extensive experience in establishing new companies, negotiating and closing venture capital financings, in-licensing technologies, and developing and implementing corporate and business development strategies. He also has a successful track record in structuring, negotiating, and documenting strategic deals with both public and private companies. He joined the firm in 2016.
Richard was formerly a partner with WilmerHale. He has previously worked in the biotech industry, serving as a legal advisor and business consultant to numerous biotech companies. As principal at R.A. Hoffman Consulting, he provided entrepreneurs and early-stage biotechnology, medical device and healthcare information companies with advice on corporate and business development strategies and tactics.
Prior to his consulting work, Richard served as Vice President of Finance and Business Development at Hybridon, Inc. (now a public company, Idera Pharmaceuticals), and later served in a similar capacity at biotech company Avitech, Inc.
Representative Matters
Richard Hoffman’s practice is focused on privately held and publicly traded emerging growth companies with a strong emphasis on companies across the spectrum of the life sciences industry, including biotechnology, medical devices, diagnostics and healthcare information technology. He often serves as general counsel to his clients, closely advising management teams and boards of directors on a wide variety of matters throughout the company’s life cycle, including company formation, private equity financings, public offerings, mergers and acquisitions, strategic collaborations, commercial transactions, corporate governance and general corporate matters. Richard also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments and company-initiation activities.
Select client representations include the following:
- Anthos Therapeutics in its up to $3.1 billion acquisition by Novartis
- Deciphera Pharmaceuticals in its $2.4 billion acquisition by Ono
- Talaris Therapeutics in its combination with Tourmaline Bio
- Ikena Oncology in its combination with Inmagene Biopharmaceuticals
- TriNetX in its acquisition of Custodix
- Syntimmune in its $1.2 billion acquisition by Alexion
- PepGen in its $108 million IPO and subsequent follow on offerings
- Ikena Oncology in its $144 million IPO and subsequent follow on offerings
- Compass Therapeutics in its $125 million public offering and subsequent follow on offering
- Deciphera in its $130 million IPO and subsequent follow-on offerings
- ConforMIS in its approximately $140 million IPO and follow-on offerings
- Eleven Biotherapeutics in its approximately $50 million IPO
- Ophthotech in its approximately $170 million IPO
- Aktis Oncology in its discovery collaboration with Eli Lilly
- Life Edit Therapeutics in its research and development collaboration with Novo Nordisk
- Ikena Oncology in its strategic collaboration with Celgene
- Harvard in its $100 million strategic R&D alliance with Deerfield Management through Lab1636
- Harvard in its license to Beam Therapeutics of base editing technologies for treating human disease
- Fedora Pharmaceuticals in its $750 million development and commercialization collaboration with Roche
- MyoKardia in its $187.5 million development and commercialization collaboration with LianBio
- Ablexis in its business development and licensing efforts, including licenses with Almirall, Janssen, Novartis, Teva and Tri-Institutional Discovery Institute, and the structuring and negotiation of its novel consortium model of initial licenses
- GRIN Therapeutics in its foundational in-license, formation and series preferred financings
- Stelexis Biosciences in its foundational in-license, formation and series preferred financings
- IMIDomics in its series preferred financings
- Anthos Therapeutics in its foundational in-license, formation and series preferred financings
- Nuvelution in its formation and series preferred financings
- Syntimmune in its foundational in-licenses, formation and series preferred financings
- Aktis Oncology in its discovery collaboration with Eli Lilly
- Life Edit Therapeutics in its research and development collaboration with Novo Nordisk
- Ikena Oncology in its foundational in-license, formation and series preferred financings
- Cullinan Oncology in its foundational in-licenses, formation and financing of asset subsidiaries
- Cydan in its option and license agreements, including those associated with Tiburio, Imara and Vtesse
- Blackstone Life Sciences in multiple product financing transactions, including its $250 million product development and commercialization financing with Autolus Therapeutics and $400 million product development and commercialization financing with Ferring Pharmaceuticals
- Abingworth in multiple product financing transactions, including its $210 million product development financing with Gilead and $150 million product development financing with Teva
- Ascenta Capital in various venture investments
- Deerfield Management in various venture investments
Credentials
Education
JD
Columbia Law School
Masters of Business Admin
The Wharton School at the University of Pennsylvania
BABiochemical Sciences
Harvard College
Admissions
Bars
- Massachusetts
- District of Columbia
- Maryland
Recognition & Awards
Publications
- Biotechnology Industry Organization: 2016 BIO International Convention San Francisco, California, June 6-9, 2016
- Biotechnology Industry Organization: 2015 BIO International Convention Philadelphia, Pennsylvania, June 13-18, 2015
- Biotechnology Industry Organization: 2014 BIO International Convention San Diego, California June 23-26 2014
- MPM Capital’s 13th Annual Healthcare Leaders Summit Bal Harbour, Florida, May 20-21, 2014